Clinical trials: Substance-Related Disorder
Tobacco Dependence
Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product.
A comparison of three products for oral nicotine replacement with respect to pharmacokinetics after multiple-doses of nicotine.
- Trial name
- NCT01084707
- Testing
- Oral Nicotine, Nicotine Lozenge, Nicotine gum
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- McNeil AB
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals
Alcohol Consumption, Alcohol Abuse
Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer
The goal of the proposed research is to complete the development of a web-based program to train Employee Assistance Program (EAP) and EAP-affiliated managed behavioral health organization (MBHO) practitioners to conduct…
- Trial name
- BigAl2 (NCT02489032)
- Testing
- SBIRT Training & Support Tool, Waitlist Control
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Hepatic Cirrhosis, Alcoholism
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
The purpose of this study is to evaluate the effect of varying degrees of hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of pasireotide s.c. in subjects.
- Trial name
- NCT00698464
- Testing
- Pasireotide
- Where
- 4 sites in United States, Belgium and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alcohol Use Disorder
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.
- Trial name
- NCT02511886
- Testing
- Arbaclofen Placarbil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indivior Inc.
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071988
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Substance Use
Peer-to-peer Tobacco and ENDS Prevention
In Phase I, the REAL media Plus prototype will be developed and a usability test conducted among students and teachers. In Phase II a group randomized trial will be conducted among 27 high schools to evaluate the effects of REAL…
- Trial name
- PPSM (NCT03491865)
- Testing
- REAL media Plus curriculum
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Real Prevention, LLC
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071936
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Nicotine Dependence, Other Tobacco Product, Tobacco Use
Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers
The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to combustible cigarette use. This study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using…
- Conditions
- Nicotine Dependence, Other Tobacco Product, Tobacco Use, Smoking, Tobacco
- Trial name
- Diamond (NCT03463837)
- Testing
- Treatment with JUUL 5%, Virginia Tobacco, Treatment with JUUL 5%, Cool Mint, ENDS, Treatment with JUUL 5%, Mango, ENDS
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Opioid Use Disorder
The Feasibility of VR for OUD
This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their…
- Trial name
- NCT06255119
- Testing
- 3D Therapy Thrive
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- 3D Therapy, LLC
Buprenorphine, Naloxone
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
The purpose of this study is to assess the risks of abuse, misuse and adverse events related to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or its Buprenorphine High Dose (BHD) generic…
- Conditions
- Buprenorphine, Naloxone, Opiate-related Disorders, Opiate Dependence
- Trial name
- OPUS R (NCT00723697)
- Testing
- buprenorphine
- Volunteers
- 1,307 people
- Sponsor
- Indivior Inc.
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users
The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like…
- Trial name
- NCT03286218
- Testing
- Lasmiditan, Alprazolam
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD).
- Trial name
- NCT05704543
- Testing
- Buprenorphine Extended-Release Injection
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Indivior Inc.
Opioid-Related Disorders, Opiate Addiction
Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med Rec Review
To assess whether the percentage of patients with behaviors suggestive of misuse, diversion, abuse and/or addiction described in the medical record increases across pre-defined categories of increasing doctor/pharmacy shopping…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02667210
- Testing
- Medical Record Review
- Volunteers
- 590 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Tobacco Dependence
Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products
Single-dose nicotine pharmacokinetics with four oral nicotine replacement products. A study in healthy smokers.
- Trial name
- NCT01234896
- Testing
- Nicotine Medicated Gum, 4 mg Nicotine Gum, 2 mg Nicotine Gum
- Where
- Sweden
- Volunteers
- 44 people
- Sponsor
- McNeil AB
Opioid Use Disorder
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication.
- Trial name
- NCT06021431
- Testing
- MORE-VR, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- BehaVR LLC
Tobacco Dependence
Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Therapy and Nicotine Gum
A comparison of two products for oral nicotine replacement with respect to relief of urges to smoke after single doses of nicotine.
- Trial name
- NCT01368016
- Testing
- Nicotine
- Where
- 2 sites in Sweden
- Volunteers
- 346 people
- Sponsor
- McNeil AB
Alcohol Abuse
Adaptive Goal-Directed Adherence Tracking and Enhancement
Talaria, Inc., has designed an adherence tracking and enhancement system, called AGATE, which uses the text messaging and internet capabilities of modern cellular phones to address the problem of medication adherence in clinical…
- Trial name
- AGATE (NCT01349985)
- Testing
- AGATE, SASED
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Talaria, Inc
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901328
- Testing
- CB-5945
- Volunteers
- 49 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Tobacco Dependence
Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum
This study examines the bioequivalence between an oral nicotine replacement product and Nicorette® gum.
- Trial name
- NCT01152749
- Testing
- Nicotine, Nicotine Gum
- Where
- Sweden
- Volunteers
- 76 people
- Sponsor
- McNeil AB